Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Investigating Attorney, Physician Beefs With Bayer’s Essure PMA

This article was originally published in The Gray Sheet

Executive Summary

FDA is investigating claims in a Citizen’s Petition by plaintiff’s attorneys that patients’ responses to the Essure permanent birth control device were tampered with in the pivotal trial, and two gynecologists' complaints of inflated marketing.


Related Content

FDA Says Bayer's Response To Essure Investigation Satisfactory; Approves Product Label
Six-Year Study Will Compare Bayer’s Essure With Tubal Ligation
Next Steps For Bayer’s Essure Device Coming In February, FDA Says
Essure Panel Stresses Need For Patient Follow-Up, But Stressed-Out Patients Say, ‘Recall It’
Expect Bayer To Get Heat At FDA Advisory Panel Over Essure Adverse Events, Doc Training
Bayer Buys Essure Contraceptive-Maker Conceptus For $1.1 Billion


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts